AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28081162 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional treatment (stenting and/or balloon angioplasty)
Number of subjects: 52
Study 28081172 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 75
Study 28081172 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann-correlated intraocular pressure (IOPg)
Number of subjects: 75
Study 28081172 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal-compensated intraocular pressure (IOPcc)
Number of subjects: 75
Study 28081172 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness (CCT)
Number of subjects: 75
Study 28081172 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpatory assessment of IOP
Number of subjects: 75
Study 28081172 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal resistance factor (CRF)
Number of subjects: 75
Study 28081172 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal hysteresis (CH)
Number of subjects: 75
Study 28081172 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal density
Number of subjects: 75
Study 28081172 — intervention group
Group type: EXPERIMENTAL
Intervention: IOPcc
Number of subjects: 75
Study 28081178 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and communication technology intervention to increase linkage to community care
Number of subjects: 110
Study 28081780 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET imaging for vascular inflammation measurement (maxTBR)
Number of subjects: 51
Study 28081820 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT (aspirin plus thienopyridine)
Number of subjects: 795
Study 28081820 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 795
Study 28081867 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilocus markers of WNT2
Number of subjects: 391
Study 28081867 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of FOXP2
Number of subjects: 391
Study 28081867 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP of WNT2
Number of subjects: 391
Study 28081885 — intervention group
Group type: EXPERIMENTAL
Intervention: All-rounders cluster (low screen time, healthy eating pattern, moderate physical activity/sedentary behavior)
Number of subjects: 5759
Study 28081885 — intervention group
Group type: COMPARATOR
Intervention: Sitters cluster (high sedentary behavior)
Number of subjects: 5759
Study 28081885 — intervention group
Group type: COMPARATOR
Intervention: Junk-food screenies cluster (high screen time/unhealthy eating pattern)
Number of subjects: 5759
Study 28081885 — intervention group
Group type: COMPARATOR
Intervention: Actives cluster (high physical activity)
Number of subjects: 5759
Study 28081914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg intravenous every 2 weeks until disease progression or unacceptable toxic effects)
Number of subjects: 33
Study 28081914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 33
Study 28081953 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 regimen of chemotherapy
Number of subjects: 442
Study 28081953 — intervention group
Group type: EXPERIMENTAL
Intervention: >1 regimen of chemotherapy
Number of subjects: 442
Study 28081953 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies in addition to chemotherapy
Number of subjects: 442
Study 28081953 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 442
Study 28081972 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 20
Study 28081972 — intervention group
Group type: COMPARATOR
Intervention: No DMARD
Number of subjects: 20
Study 28082379 — intervention group
Group type: EXPERIMENTAL
Intervention: Five years of specialised early intervention (SEI) treatment (n=197)
Number of subjects: 400
Study 28082379 — intervention group
Group type: COMPARATOR
Intervention: Two years of specialised early intervention (SEI) plus three years of treatment as usual (control; n=203)
Number of subjects: 400
Study 28082419 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy for primary prevention of SCD
Number of subjects: 5485
Study 28082434 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study 28082434 — intervention group
Group type: EXPERIMENTAL
Intervention: PET scans
Number of subjects: 0
Study 28084038 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab injections monthly
Number of subjects: 40
Study 28084683 — intervention group
Group type: EXPERIMENTAL
Intervention: High antibiotic use
Number of subjects: 561
Study 28084683 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 561
Study 28084683 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 561
Study 28084854 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aphasia and Apraxia of Speech Treatment (CAAST)
Number of subjects: 4
Study 28084883 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushing interval of implanted ports once every 3 months
Number of subjects: 87
Study 28085911 — intervention group
Group type: EXPERIMENTAL
Intervention: STA-Liatest® D-Dimers and imaging in OUS
Number of subjects: 1060
Study 28085911 — intervention group
Group type: COMPARATOR
Intervention: STA-Liatest® D-Dimers and imaging in the US
Number of subjects: 1060
Study 28085911 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging procedures for PE diagnosis in OUS
Number of subjects: 1060
Study 28085911 — intervention group
Group type: COMPARATOR
Intervention: Imaging procedures for PE diagnosis in the US
Number of subjects: 1060
Study 28085911 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping investigation with negative D-dimers in OUS
Number of subjects: 1060
Study 28085911 — intervention group
Group type: COMPARATOR
Intervention: Stopping investigation with negative D-dimers in the US
Number of subjects: 1060
Study 28085911 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of imaging in moderate PTP with negative DD in OUS
Number of subjects: 1060
Study 28085911 — intervention group
Group type: COMPARATOR
Intervention: Use of imaging in moderate PTP with negative DD in the US
Number of subjects: 1060
Study 28086010 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction of antipsychotics (olanzapine or risperidone) by up to 40%
Number of subjects: 42
Study 28086010 — intervention group
Group type: EXPERIMENTAL
Intervention: D2/3R occupancy of 66% or higher
Number of subjects: 42
Study 28086010 — intervention group
Group type: EXPERIMENTAL
Intervention: D2/3R occupancy threshold for hyperprolactinemia
Number of subjects: 42
Study 28086164 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive lacosamide (400mg/day during titration, 100-800mg/day during maintenance)
Number of subjects: 49
Study 28086164 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive lacosamide
Number of subjects: 49
Study 28086754 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighed food intake assessment over three days (main plate items), estimations of side dishes, beverages, and snacks compared to Dietary Reference Intake.
Number of subjects: 639
Study 28086754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status, nutritional risk; disease conditions, medication, and diet prescriptions; oral health exam, signs of swallowing difficulty and olfactory ability; observed eating behaviours, type and number of staff assisting with eating; food and foodservice satisfaction.
Number of subjects: 639
Study 28086754 — intervention group
Group type: EXPERIMENTAL
Intervention: Function, cognition, depression, and pain assessed using interRAI LTCF.
Number of subjects: 639
Study 28086754 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and psychosocial aspects of dining rooms assessed by researchers.
Number of subjects: 639
Study 28086754 — intervention group
Group type: EXPERIMENTAL
Intervention: Management completed a questionnaire on home characteristics, menu development, food production, out-sourcing of food, staffing levels, and staff training.
Number of subjects: 639
Study 28086754 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical regression models used to determine factors independently associated with energy and protein intake.
Number of subjects: 639
Study 28086754 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportions of residents at risk of inadequate diets will be determined.
Number of subjects: 639
Study 28086778 — intervention group
Group type: EXPERIMENTAL
Intervention: cFFR (contrast-based fractional flow reserve)
Number of subjects: 763
Study 28086778 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 763
Study 28086778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd/Pa (pressure distal to aortic pressure)
Number of subjects: 763
Study 28086778 — intervention group
Group type: COMPARATOR
Intervention: cFFR
Number of subjects: 763
Study 28086778 — intervention group
Group type: COMPARATOR
Intervention: Pd/Pa
Number of subjects: 763
Study 28086778 — intervention group
Group type: COMPARATOR
Intervention: iFR
Number of subjects: 763
Study 28086781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal implantation of stromal vascular fraction (SVF) plus platelet rich plasma (PRP)
Number of subjects: 15
Study 28086825 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) - 37 Gy in 5 fractions
Number of subjects: 60
Study 28086870 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-based counseling by community health agents (CHAs)
Number of subjects: 57
Study 28086942 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally fractionated radiotherapy (cfRT) at dose level 1 (54Gy)
Number of subjects: 19
Study 28086942 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally fractionated radiotherapy (cfRT) at dose level 2 (58Gy)
Number of subjects: 19
Study 28086942 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally fractionated radiotherapy (cfRT) at dose level 3 (62Gy)
Number of subjects: 19
Study 28086942 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with cfRT
Number of subjects: 19
Study 28086942 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with cfRT at dose level 3 (62Gy)
Number of subjects: 19
Study 28087181 — intervention group
Group type: EXPERIMENTAL
Intervention: 1h algorithm with hs-TnI cutoff of 6ng/L
Number of subjects: 1625
Study 28087181 — intervention group
Group type: COMPARATOR
Intervention: 99th percentile cutoff of 27ng/L
Number of subjects: 1625
Study 28087508 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 9306
Study 28087508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 9306
Study 28087508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9306
Study 28087540 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed consensus diagnostic criteria for iMCD
Number of subjects: 244
Study 28087540 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Criteria
Number of subjects: 244
Study 28087540 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor Criteria
Number of subjects: 244
Study 28087540 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion criteria
Number of subjects: 244
Study 28087556 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment in patients with blunt head injury
Number of subjects: 3566
Study 28087556 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of symptoms in patients with GCS=15
Number of subjects: 3566
Study 28087556 — intervention group
Group type: EXPERIMENTAL
Intervention: INR measurement in patients with GCS=15
Number of subjects: 3566
Study 28087826 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI group 1 (cortical, brainstem, and cerebellar malformations)
Number of subjects: 34
Study 28087826 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI group 2 (cortical and cerebellar malformations)
Number of subjects: 34
Study 28087826 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI group 3 (normal)
Number of subjects: 34
Study 28087826 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 34
Study 28088206 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiGraph
Number of subjects: 55
Study 28088206 — intervention group
Group type: COMPARATOR
Intervention: Pedometer
Number of subjects: 55
Study 28088206 — intervention group
Group type: COMPARATOR
Intervention: IPAQ
Number of subjects: 55
Study 28088395 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum lactate ≥ 2.5 mmol/L
Number of subjects: 110
Study 28088395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate: pyruvate (L:P) ratio ≥ 25
Number of subjects: 110
Study 28088395 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial lactate or L:P
Number of subjects: 110
Study 28088398 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program for 8 weeks
Number of subjects: 18
Study 28088807 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior circulation stroke (PCS)
Number of subjects: 2101
Study 28088807 — intervention group
Group type: COMPARATOR
Intervention: Anterior circulation stroke (ACS)
Number of subjects: 2101
Study 28089238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg orally twice a day
Number of subjects: 41
Study 28089456 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 weeks of interval exercise training
Number of subjects: 16
Study 28089618 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous (par)enteral nutrition with protein intake 1.0-3.7 g/kg/day
Number of subjects: 8
Study 28089635 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (400 mg recommended phase 2 dose) plus rituximab (375 mg/m2 monthly)
Number of subjects: 49
Study 28089635 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (400 mg) plus rituximab
Number of subjects: 49
Study 28089635 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (50 mg)
Number of subjects: 49
Study 28089635 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (20 mg)
Number of subjects: 49
Study 28089635 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus rituximab
Number of subjects: 49
Study 28089762 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent weekly carboplatin and paclitaxel with 74 Gy of radiation in 37 fractions (2-Gy daily fractions)
Number of subjects: 25
Study 28090295 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled trepostinil
Number of subjects: 6
Study 28090299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg/day for the first 4 weeks, then 40 mg/day for the subsequent 20 weeks
Number of subjects: 12
Study 28090299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 12
Study 28090332 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss maintenance <7% (Group A)
Number of subjects: 129
Study 28090332 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss maintenance ≥7% (Group B)
Number of subjects: 129
Study 28090335 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down treatment with 5 Infliximab (IFX) infusions combined with azathioprine (AZA).
Number of subjects: 0
Study 28090335 — intervention group
Group type: COMPARATOR
Intervention: Step-up treatment with standard induction treatment (oral prednisolone or exclusive enteral nutrition) combined with azathioprine (AZA) as maintenance treatment.
Number of subjects: 0
Study 28090335 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down treatment
Number of subjects: 0
Study 28090335 — intervention group
Group type: COMPARATOR
Intervention: Step-up treatment
Number of subjects: 0
Study 28090670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nogo-B positive Kupffer cells in ALD patients
Number of subjects: 30
Study 28090670 — intervention group
Group type: EXPERIMENTAL
Intervention: WT mice on Lieber-DeCarli ethanol liquid diet (5% ethanol) for 6 weeks
Number of subjects: 30
Study 28091980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m maraciclatide
Number of subjects: 39
Study 28091980 — intervention group
Group type: COMPARATOR
Intervention: Tc-99m sestamibi
Number of subjects: 39
Study 28092464 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support/behavior skills interest
Number of subjects: 405
Study 28092464 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordance in parent/adolescent dyad responses
Number of subjects: 405
Study 28092464 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent weight-loss goals
Number of subjects: 405
Study 28093033 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28093823 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep
Number of subjects: 121
Study 28094171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Treatment (CRT) for 12 weeks
Number of subjects: 63
Study 28094314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous (IV) esomeprazole for 72 hours
Number of subjects: 0
Study 28094314 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 72 hours
Number of subjects: 0
Study 28095791 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred and thriving-promoting intervention
Number of subjects: 6
Study 28095791 — intervention group
Group type: COMPARATOR
Intervention: Inert control group
Number of subjects: 6
Study 28095838 — intervention group
Group type: EXPERIMENTAL
Intervention: COMFORT intervention (family conversations led by a designated requester, separation of donation offer from end-of-life discussion, structured family donation conversation)
Number of subjects: 140
Study 28095838 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention usual practice
Number of subjects: 140
Study 28096100 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 28096100 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 28096099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-saturated-fat (HF) diet
Number of subjects: 46
Study 28096099 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich, low-fat diet
Number of subjects: 46
Study 28096259 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 10
Study 28096259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal and infusion of exogenous glucose-dependent insulinotropic polypeptide (GIP)
Number of subjects: 10
Study 28096259 — intervention group
Group type: COMPARATOR
Intervention: Lean control subjects
Number of subjects: 10
Study 28096374 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 0
Study 28096387 — intervention group
Group type: EXPERIMENTAL
Intervention: GBT440
Number of subjects: 0
Study 28096387 — intervention group
Group type: EXPERIMENTAL
Intervention: AES103
Number of subjects: 0
Study 28096387 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic method
Number of subjects: 0
Study 28096478 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB device
Number of subjects: 150
Study 28097013 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglucosamine (2 tablets x 2)
Number of subjects: 64
Study 28097013 — intervention group
Group type: COMPARATOR
Intervention: Orlistat (1 capsule x 3)
Number of subjects: 64
Study 28097230 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28097231 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein disulfide isomerase inhibition
Number of subjects: 0
Study 28099715 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 44
Study 28099715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 28100190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nutrition and resistance exercise intervention
Number of subjects: 25
Study 28100441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dot app (Dynamic Optimal Timing) for pregnancy prevention
Number of subjects: 1200
Study 28100441 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1200
Study 28100512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose in mixed meals
Number of subjects: 0
Study 28100512 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose in mixed meals
Number of subjects: 0
Study 28100523 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative RHI measurement
Number of subjects: 31
Study 28100523 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative L-arginine measurement
Number of subjects: 31
Study 28100523 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ADMA measurement
Number of subjects: 31
Study 28100523 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative biopterin metabolites measurement
Number of subjects: 31
Study 28100523 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between logAUC(l-arginine/ADMA) and logAUC(RHI)
Number of subjects: 31
Study 28100523 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between logAUC(L-arginine/ADMA) and logAUC(BH4)
Number of subjects: 31
Study 28100523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin I measurement
Number of subjects: 31
Study 28100530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (2 mcg/kg bolus for 10 minutes)
Number of subjects: 30
Study 28100545 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exposure to ambient air pollution (specific pollutants not detailed)
Number of subjects: 520
Study 28100627 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth/differentiation factor-15
Number of subjects: 86
Study 28100627 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin
Number of subjects: 86
Study 28100627 — intervention group
Group type: EXPERIMENTAL
Intervention: Agouti-related protein
Number of subjects: 86
Study 28100627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitinase-3-like protein 1
Number of subjects: 86
Study 28100627 — intervention group
Group type: EXPERIMENTAL
Intervention: C-C motif chemokine 20
Number of subjects: 86
Study 28100627 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty acid-binding protein
Number of subjects: 86
Study 28100627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor receptor 1
Number of subjects: 86
Study 28100627 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-related apoptosis-inducing ligand
Number of subjects: 86